U.S. markets close in 6 hours 20 minutes
  • S&P 500

    +43.59 (+1.00%)
  • Dow 30

    +315.55 (+0.92%)
  • Nasdaq

    +118.75 (+0.88%)
  • Russell 2000

    -27.57 (-1.38%)
  • Crude Oil

    +0.85 (+0.97%)
  • Gold

    -31.60 (-1.73%)
  • Silver

    -1.02 (-4.27%)

    -0.0083 (-0.74%)
  • 10-Yr Bond

    -0.0180 (-0.97%)

    -0.0063 (-0.47%)

    +0.7000 (+0.61%)

    -1,386.41 (-3.62%)
  • CMC Crypto 200

    +26.30 (+3.21%)
  • FTSE 100

    +83.68 (+1.12%)
  • Nikkei 225

    -841.03 (-3.11%)

Did You Miss Halozyme Therapeutics' (NASDAQ:HALO) Whopping 399% Share Price Gain?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • HALO

We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to find, but they can generate massive returns over long periods. Don't believe it? Then look at the Halozyme Therapeutics, Inc. (NASDAQ:HALO) share price. It's 399% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. It's even up 9.4% in the last week.

Check out our latest analysis for Halozyme Therapeutics

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During the five years of share price growth, Halozyme Therapeutics moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here. Since the company was unprofitable five years ago, but not three years ago, it's worth taking a look at the returns in the last three years, too. Indeed, the Halozyme Therapeutics share price has gained 121% in three years. Meanwhile, EPS is up 35% per year. This EPS growth is reasonably close to the 30% average annual increase in the share price (over three years, again). That suggests that the market sentiment around the company hasn't changed much over that time. Rather, the share price has approximately tracked EPS growth.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).


We know that Halozyme Therapeutics has improved its bottom line over the last three years, but what does the future have in store? You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

We're pleased to report that Halozyme Therapeutics shareholders have received a total shareholder return of 83% over one year. That gain is better than the annual TSR over five years, which is 38%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for Halozyme Therapeutics (2 are a bit unpleasant!) that you should be aware of before investing here.

But note: Halozyme Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.